Attention-Deficit/Hyperactivity Disorder Subtypes Defined by Cognition Have a Distinct Neural and Clinical Profile and Differ in Response to Atomoxetine.

objectiveAttention-deficit/hyperactivity disorder (ADHD) is clinically and etiologically heterogeneous across multiple levels of organization. This study sought to parse the heterogeneity of ADHD by identifying cognitive subtypes based on common features of ADHD, including inhibitory control, sustained attention, and working memory. To validate the subtypes, constructs at other meaningful levels of organization were used: quantitative electroencephalogram (qEEG), clinical symptoms, and response to treatment with atomoxetine and methylphenidate.

methodHierarchical cluster analysis of cognitive measures defined clusters in 1 clinical sample (n = 112). Replication was tested in a second, held-out clinical sample (n = 336). Cluster subtypes were assessed for neural validation using resting-state qEEG and heart rate and for clinical applicability using ADHD and anxiety symptom ratings. Further, clusters were assessed for differential treatment response after 6 weeks of atomoxetine or methylphenidate.

resultsTwo clusters defined by specific cognitive profiles were identified and replicated. The inhibitory control subtype was distinguished by more activity in qEEG delta (β = -.47, p = 4.89 × 10

conclusionCognitive performance appears to be effective for identifying ADHD subtypes that have a distinct neural basis and that may particularly benefit from nonstimulant medications such as atomoxetine. PLAIN LANGUAGE SUMMARY: Current attention-deficit/hyperactivity disorder (ADHD) subtypes, based on parent-reported symptoms, are not very useful for clinical predictions or research breakthroughs. This study identified new ADHD subtypes using computerized attention-based tasks and compared these new subtypes' responses to 2 ADHD medications: methylphenidate (stimulant) and atomoxetine (nonstimulant). A subtype with a more impulsive, error-prone style had higher resting heart rates and electroencephalogram (EEG) differences and responded well to both medications. A subtype with more lapses in sustained attention responded well only to methylphenidate. These results are a step toward targeting treatments based on attention testing. These novel subtypes could also help understand underlying biological mechanisms. DIVERSITY & INCLUSION STATEMENT: We worked to ensure sex and gender balance in the recruitment of human participants. We worked to ensure race, ethnic, and/or other types of diversity in the recruitment of human participants. We worked to ensure that the study questionnaires were prepared in an inclusive way. One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented sexual and/or gender groups in science. We actively worked to promote sex and gender balance in our author group. The author list of this paper includes contributors from the location and/or community where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. While citing references scientifically relevant for this work, we also actively worked to promote sex and gender balance in our reference list. While citing references scientifically relevant for this work, we also actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our reference list. CLINICAL TRIAL REGISTRATION INFORMATION: International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder; https://www. CLINICALTRIALS: gov/study/NCT00863499.